[1. Capodanno D, Angiolillo DJ. Triple Antithrombotic Therapy at the Intercept Between Threats and Opportunities: Don’t Throw Out the Baby With the Bath Water. JACC Cardiovasc Interv. 2017;10:1086-1088.10.1016/j.jcin.2017.03.028]Search in Google Scholar
[2. Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126:1185-1193.10.1161/CIRCULATIONAHA.112.114967]Search in Google Scholar
[3. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019. pii: S0735-1097(19)30209-8.10.1161/CIR.0000000000000665]Search in Google Scholar
[4. Mantis C, Alexopoulos D. Antithrombotic treatment in atrial fibrillation patients undergoing PCI: Is dual therapy the winner? Thrombosis Research. 2019;176:133-139.10.1016/j.thromres.2019.02.022]Search in Google Scholar
[5. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39:213-254.10.1093/eurheartj/ehx419]Search in Google Scholar
[6. Senoo K, Lane D, Lip GY. Stroke and Bleeding Risk in Atrial Fibrillation. Korean Circ J. 2014;44:281.10.4070/kcj.2014.44.5.281]Search in Google Scholar
[7. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2015;50:e1-e88.]Search in Google Scholar
[8. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107-1115.10.1016/S0140-6736(12)62177-1]Search in Google Scholar
[9. Fiedler KA, Maeng M, Mehilli J, et al. Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. J Am Coll Cardiol. 2015;65:1619-1629.10.1016/j.jacc.2015.02.05025908066]Search in Google Scholar
[10. Hammersley D, Signy M. Navigating the choice of oral anticoagulation therapy for atrial fibrillation in the NOAC era. Ther Adv Chronic Dis. 2017;8:165-176.10.1177/2040622317720106569214029201334]Search in Google Scholar
[11. Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016;375:2423-2434.10.1056/NEJMoa161159427959713]Search in Google Scholar
[12. Oldgren J, Steg PG, Hohnloser SH, et al. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J. 2019. pii: ehz059.10.1093/eurheartj/ehz059651483830793734]Search in Google Scholar
[13. Cannon CP, Bhatt DL, Oldgren J, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017;377:1513-1524.10.1056/NEJMoa170845428844193]Search in Google Scholar
[14. Lopes RD, Vora AN, Liaw D, et al. An open-label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: rationale and design of the AUGUSTUS trial. Am Heart J. 2018;200:17-23.10.1016/j.ahj.2018.03.00129898844]Search in Google Scholar
[15. Lopes RD, Heizer G, Aronson R, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019;380:1509-1524.10.1056/NEJMoa181708330883055]Search in Google Scholar